- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Company Invited to Tokyo ICS-Nanotech 2005 Conference to Accept Award and Deliver Address on Biophan’s Nano-based Advances and Solutions
Biophan Technologies, Inc. (OTCBB:BIPH), a developer of next-generation biomedical technology, announced that it has been named to receive the Nano Science and Technology Institute’s (NSTI) Early Stage Company Award, to be presented at its February 23-25 conference in Tokyo, Japan.
The ICS-NSTI‘s Early Stage Company Award recognizes superior innovation and achievement by development-stage companies providing leadership in the science and business of nanotechnology. NSTI is a respected organization that works to promote education, research and business development in nanoscience and related fields. Biophan has developed a rich portfolio of patents and intellectual property that provide a range of solutions to important problems in healthcare, among them, the application of nanotechnology to improve the safety and effectiveness of Magnetic Resonance Imaging (MRI), one of medicine’s most important diagnostic tools.
“We’re gratified that Biophan’s continuing advances in nanotechnology have been recognized by the Nano Science and Technology Institute,” said Michael Weiner, Biophan’s CEO. “The award is an important validation of Biophan’s research and development in applications of nanotechnology that have the potential to enable substantial advances in healthcare and the life sciences, and to incorporate nanotechnology into the multi-billion-dollar worldwide markets in medical devices, drug delivery, power systems, and other sectors. Our company is built on the development of intellectual property from the laboratory to the marketplace, and the ISC-NSTI Early Stage Company Award helps demonstrate our contributions to the nanoscience space.”
The ICS-NSTI Early Stage Company Award includes a modest cash award and an invitation for Biophan’s representative to address attendees at the Tokyo conference, to present the Company’s advanced nanotechnology-based biomedical solutions and research. Approximately 20,000 nanoscience research and business professionals are expected to attend the conference.
In addition, Biophan has been accepted by NSTI into its Nanotech Ventures program commencing at the Nanotech 2005 Conference and Trade Show on May 8-12, in Anaheim, California. Biophan will make a presentation at that gathering, as part of the organization’s Nanotech 2005 Early Stage Company Review, a forum designed to allow companies to showcase their technologies and solutions.
About the Nano Science and Technology Institute
The Nano Science and Technology Institute (NSTI) is chartered with the promotion and integration of nano and other advanced technologies through education, technology and business development. NSTI accomplishes this mission through its offerings of consulting services, continuing education programs, scientific and business publishing and community outreach. NSTI produces the annual Nanotech conference and trade show, the most comprehensive international nanotechnology convention in the world. NSTI also produces BioNano and Stem Cell Strategies conferences. NSTI was founded in 1997 as a result of the merger between various scientific societies, and is headquartered in Cambridge, Mass., with additional offices in California and Switzerland. For more information about NSTI, visit, www.nsti.org/
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin-film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 104 U.S. patents, licenses, or applications. This total includes 30 issued U.S. patents, 6 recently-allowed applications that will issue as patents in the near future, and 68 pending applications at various stages of examination at the U.S. Patent and Trademark Office. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE: BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com. To view the Company’s Investor Fact Sheet, or ongoing installments of “Biophan 101” informational videos about aspects of the Company’s next-generation biomedical solutions, visit www.trilogy-capital.com/tcp/html/biophan.htm.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Particle Works creates range of high performance quantum dots February 23rd, 2017
GLOBALFOUNDRIES Announces Availability of 45nm RF SOI to Advance 5G Mobile Communications: Optimized RF features deliver high-performance solutions for mmWave beam forming applications in 5G smartphones and base stations February 22nd, 2017